Lung Transplant — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Lung transplantation is a complex thoracic surgical procedure in which one or both diseased lungs are replaced with healthy lungs from a brain-dead or donation-after-cardiac-death (DCD) donor to restore respiratory function in patients with end-stage pulmonary disease. Bilateral sequential lung transplantation (BSLT) — replacing both lungs through a clamshell (bilateral thoracosternotomy) or bilateral thoracotomy incision — is now preferred for the majority of diagnostic categories because it provides superior lung function, better long-term survival, and eliminates native lung-related complications (native lung hyperinflation in COPD, infection in cystic fibrosis). Single lung transplantation (SLT) is used selectively in older patients with idiopathic pulmonary fibrosis (IPF) to maximise donor organ utilisation. Living-donor lobar transplantation, in which lobes from two healthy living donors are implanted, is performed in selected paediatric and young adult recipients at specialised Asian centres. Extracorporeal membrane oxygenation (ECMO) as a bridge to transplantation has expanded the eligible recipient pool by supporting critically ill patients awaiting an organ. Cardiopulmonary bypass (CPB) or ECMO maintains circulation and gas exchange during the procedure when the patient cannot tolerate single-lung ventilation.

This treatment represents an important component of modern medical management, supported by clinical evidence from multiple randomised controlled trials and systematic reviews. Treatment protocols are continually refined based on emerging evidence to optimise patient outcomes while minimising treatment burden.

Patient suitability is assessed through a structured multidisciplinary evaluation incorporating clinical history, physical examination findings, and results of relevant investigations. Treatment planning considers the full clinical context including disease characteristics, patient comorbidities, functional status, and individual treatment goals to ensure the most appropriate therapeutic approach is selected for each patient.

Lung transplantation is indicated for patients with end-stage pulmonary disease with projected 2-year mortality exceeding 50% without transplantation, who have exhausted maximal medical therapy. The four most common diagnostic categories globally are: chronic obstructive pulmonary disease (COPD) with severe airflow obstruction (FEV1 below 20–25% predicted), particularly with homogeneous emphysema or elevated hyperinflation ratio; idiopathic pulmonary fibrosis (IPF) with rapid decline, DLco below 40% predicted, or 6-minute walk distance below 250 metres; cystic fibrosis with FEV1 below 30% or rapidly declining, supplemental oxygen dependence, and frequent hospitalisations; and pulmonary arterial hypertension (PAH) with WHO Class III–IV symptoms and right heart failure unresponsive to maximal medical therapy including prostanoids. Other indications include alpha-1 antitrypsin deficiency emphysema, lymphangioleiomyomatosis (LAM), sarcoidosis, and bronchiectasis. Absolute contraindications include active malignancy (current or within 2–5 years), irreversible multi-organ dysfunction, severe musculoskeletal disease incompatible with post-transplant rehabilitation, and active or recent substance abuse. Relative contraindications include BMI over 35 kg/m², prior major thoracic surgery, active systemic infection, and poor functional status (unable to participate in pre-transplant rehabilitation).

The recipient is listed with a national transplant authority (UNOS in the USA, NHSBT in the UK) using allocation algorithms based on medical urgency and disease severity scores (LAS — Lung Allocation Score). When a suitable donor offer is accepted, the recipient is called to hospital and optimised for surgery. Under general anaesthesia with double-lumen endotracheal tube enabling single-lung ventilation, bilateral sequential transplantation begins with the most diseased native lung. A lateral thoracotomy or clamshell incision is made. The diseased lung is excised: hilar dissection divides the main bronchus, pulmonary artery, and two pulmonary veins. The donor lung, preserved in cold Perfadex solution, is implanted: bronchial anastomosis is performed first (end-to-end, with omental or peribronchial tissue wrapping to promote neovascularisation), then pulmonary artery anastomosis, then a combined venoatrial anastomosis at the left atrial cuff. Perfusion is carefully restored while monitoring for reperfusion pulmonary oedema. The procedure is repeated on the contralateral side. Extracorporeal support (ECMO or CPB) is used when hypoxia or haemodynamic instability occurs during single-lung ventilation — used in approximately 30–50% of bilateral transplants at experienced centres. Chest drains are placed bilaterally and the patient transferred to the ICU mechanically ventilated.

The procedure is performed in an appropriately equipped facility by experienced specialist clinicians. Prior to commencement, the patient undergoes pre-procedural assessment including vital signs measurement, review of relevant investigations, and confirmation of informed consent. Intravenous access is established and monitoring equipment including ECG, pulse oximetry, and blood pressure monitoring is applied.

The procedural site is prepared according to aseptic technique standards. Anaesthesia or analgesia is administered as appropriate for the specific procedure and patient needs, ranging from local anaesthesia for minor procedures to regional or general anaesthesia for more complex interventions.

The procedure is performed under direct visualisation or image guidance as appropriate. Key technical steps are executed with attention to anatomical landmarks and patient safety parameters. Haemostasis is achieved and confirmed before completion. Post-procedural assessment includes clinical evaluation of the immediate result, complication surveillance, and documentation of the procedure.

Recovery room monitoring continues until the patient meets defined discharge criteria. Written post-procedural instructions covering activity restrictions, wound care, medication management, and symptoms requiring urgent review are provided before discharge.

Lung transplantation significantly improves survival and quality of life compared to the natural history of end-stage lung disease across all indications. The International Society for Heart and Lung Transplantation (ISHLT) 2023 Registry Report of over 70,000 lung transplants documents: median survival of approximately 6.7 years overall; 80% 1-year and 54% 5-year survival for bilateral transplants; 5.3 years median survival for single lung transplants. Recipients with cystic fibrosis have the best outcomes (median survival over 9 years) due to their younger age and preserved cardiac function. IPF recipients have lower median survival (approximately 4.5 years) reflecting older recipient age and baseline disease severity. Quality of life improves substantially within 3–6 months of transplantation: forced expiratory volume in 1 second (FEV1) typically reaches 60–80% predicted by 12 months in bilateral transplant recipients with COPD or cystic fibrosis. Exercise capacity (6-minute walk distance) improves from under 200 metres pre-transplant to over 500 metres at 12 months in many patients. Pre-transplant oxygen dependence resolves in the majority of recipients with good primary graft function.

Lung transplantation carries the highest acute and chronic complication burden of all solid organ transplants. Primary graft dysfunction (PGD) — acute lung injury within 72 hours of transplantation from ischaemia-reperfusion injury — affects 25–35% of recipients and is the leading cause of 30-day mortality and later chronic rejection. Acute cellular rejection (ACR) occurs in 30–35% of recipients within the first year and is typically treated with pulsed methylprednisolone; most episodes resolve. Chronic lung allograft dysfunction (CLAD) — mainly bronchiolitis obliterans syndrome (BOS) from fibrotic obliteration of small airways by immune injury — affects 50% of 5-year survivors and is the leading cause of late graft failure; treatment options are limited. Infectious complications from immunosuppression are a major cause of morbidity and mortality: bacterial pneumonia (Pseudomonas, Klebsiella), CMV pneumonitis, Aspergillus, and Pneumocystis jirovecii pneumonia. Calcineurin inhibitor (tacrolimus) toxicity causes nephrotoxicity (15–30% develop CKD by 5 years), neurotoxicity, hypertension, and diabetes. Anastomotic airway complications (dehiscence, stenosis) affect 2–15% of bronchial anastomoses. PTLD (post-transplant lymphoproliferative disorder) from EBV reactivation under immunosuppression affects 1–3%.

Immediate post-operative care requires ICU admission for mechanical ventilation, typically 3–7 days for uncomplicated cases and longer for PGD. Lung protective ventilation strategies (low tidal volume 6 mL/kg, PEEP titration, permissive hypercapnia) reduce ventilator-induced lung injury in the transplanted graft. Extubation is followed by careful physiotherapy, chest percussion, and assisted cough to clear secretions from the denervated, acough-reflexed lung. Hospital stay is 3–6 weeks for uncomplicated bilateral transplants. Triple immunosuppression is standard: tacrolimus (target trough level 10–15 ng/mL initially), mycophenolate mofetil, and prednisolone, gradually tapered over 12 months. Prophylaxis against CMV (valganciclovir for 6–12 months), Pneumocystis (trimethoprim-sulfamethoxazole lifelong), and Aspergillus (voriconazole or inhaled amphotericin) is maintained. Pulmonary rehabilitation begins within days of extubation, progressing from bedside physiotherapy to formal outpatient supervised exercise programmes. Serial spirometry (FEV1 monitoring) detects BOS early. Bronchoscopy with transbronchial biopsy is scheduled at weeks 1, 3, and 6 post-transplant to detect rejection. Annual echocardiography monitors for pulmonary hypertension. Recipients require lifelong immunosuppression, medical follow-up, and education on rejection and infection symptoms.